Lowest Price Guaranteed
Pages
752
Last Updated
June 2026
View Count
28552
The global viral vector and plasmid DNA manufacturing market, valued at USD 843 million in 2025, is projected to reach USD 937 million in 2026 and USD 2,161 million by 2035, with a CAGR of 9.73% during the forecast period 2026 to 2035.
 |
To learn more about this report, request a free sample copy
Viral and non-viral vectors have emerged as indispensable tools for delivering genetic material into target cells, forming the backbone of modern cell therapies and gene therapies. By May 2025, around 30 viral vector–based therapies have received global regulatory approval, while over 500 candidates are undergoing clinical trials in the US. This surge in approvals and ongoing studies has fueled the demand for large-scale viral vector manufacturing. However, this domain is fraught with several challenges, including immunogenicity risks and the complex nature of viral vector characterization. To overcome these hurdles, developers are increasingly exploring the potential of non-viral vectors as safer and more scalable alternatives.
|
|
|
|
To meet the rising demand for vectors, the industry has introduced several process innovations. Notably, Corning Life Sciences has developed high-density cell culture systems such as HYPERStack and CellSTACKs, which leverage gas-permeable film technology to enhance vector yields. The company has also introduced automation platforms to optimize workflows, reduce manual intervention, and accelerate production timelines. These technological improvements have created momentum for more efficient, consistent, and cost-effective vector manufacturing worldwide.
|
|
|
|
Presently, over 300 industry and non-industry players across the globe are actively involved so as to support the expanding pipeline of cell therapies, gene therapies, and vector-based vaccines, as per viral vectors and plasmid DNA manufacturing market report. The growth in this sector is further fueled by investments, strategic collaborations, and facility expansions, reflecting a strong commitment towards overcoming production bottlenecks. Collectively, these developments suggest that both viral and non-viral vector manufacturing are poised for strong growth, making them key driver of the next generation of genetic medicines.
|
|
|
|
The viral vector and plasmid DNA manufacturing market analysis also highlights the likely distribution of the current and forecasted opportunity across various segments, such as scale of operation, type of vectors manufactured, application area, therapeutic area, type of manufacturer and geographical regions.
We have created three market forecast scenarios, conservative, base and optimistic, to account for future uncertainties in key parameters and enhance the robustness of our model. These scenarios outline different tracks of the industry's evolution.
The viral vector & plasmid manufacturing market is set to grow, fueled by increasing demand for gene therapies, expanding vaccine development initiatives and ongoing technological advancements in vector design and production platforms. Further, our projections show that the market will grow at a significant CAGR in the coming years, supported by expanding clinical pipelines, increasing investments and collaboration activity for scalable production platforms.
Owing to the growing research and development efforts for viral vector-based therapies, the success of early-stage clinical trials and the promising therapeutic potential of viral vector-based therapies, we believe that the viral vector and plasmid DNA manufacturing industry is likely to grow at a steady rate during the forecast period.
Several recent developments have taken place in the field, and we have outlined some of these below. These developments, even if they arose after our market report’s release, support the overall viral vector and plasmid DNA manufacturing market trends detailed in our analysis.
Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes detailed transcripts of interviews conducted with the following individuals:
Viral vector and plasmid DNA domain will mark a turning point in 2025. Industry expert’s states, “Over the past few years, interest advancements in gene therapy and cell-based treatments are revolutionizing the treatment of multiple disorders.”
The “Viral Vector and Plasmid DNA Manufacturing Market: Industry Trends and Global Forecasts, till 2035” market report features an extensive study of viral vector manufacturing (industry players) landscape, non-viral vector manufacturing (industry players) landscape, vector manufacturing (non-industry players) landscape, demand and supply analysis and market forecast and opportunity analysis, during the forecast period.
The market report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the healthcare market. Key takeaways of the market report have been briefly discussed below.
The market landscape is concentrated with the presence of over 130 viral vector manufacturers. Of these, 45% of the companies have been established post-2010 indicating the growing interest of stakeholders in this domain. Notable examples of companies (established post- 2010, in alphabetical order) include 4D Molecular Therapeutics, Abeona Therapeutics, Adverum Biotechnologies, AGC Biologics, Andelyn Biosciences, Autolus and Beacon Therapeutics.
Notably, 91% of the viral vector therapies are currently in clinical stages of development, with 80% of therapies in preclinical stages. Further, majority of the therapies are manufactured by contract manufacturers based in different countries across the globe.
The current landscape presents over 100 well-established players and new entrants that are involved in manufacturing non-viral vectors. Further, the landscape features a fragmented structure, with very large, large, mid-sized and small players headquartered across different regions.
It is worth noting that majority (close to 60%) of the manufacturers have their headquarters in North America, owing to the robust research initiatives and substantial investments made by the manufacturers in this region.
The current market landscape features over 80 organizations and more than 80% of organizations have the required capabilities to manufacture AAV vectors. Notably, close to 40% of the organizations have capability to manufacture vectors at preclinical and clinical stages. Further, majority of the organizations (90%) actively manufacture vectors for use in gene therapies, followed by cell therapies.
The technology landscape includes over 100 technologies that are utilized for manufacturing various types of vectors. Presently, 86% of the technologies are manufacturing vectors at clinical stage, followed by preclinical (63%). Additionally, majority (83%) of the technologies are being utilized for manufacturing vectors that can be used in gene therapy applications.
The global viral vector manufacturing market size is likely to be worth $ 937 million in 2026 and will reach $ 2,161 million by 2035. In terms of scale of operation, the global market highlights distribution of preclinical, clinical and commercial scales. In 2026, the clinical segment dominates the market and holds 50% of the market share, owing to the large pipeline of viral vector-based therapies in various stages of clinical trials. Further, the market size for commercial segment is likely to grow at a relatively higher CAGR of 13% during the forecast period.
North American companies are likely to dominate the global viral vector and plasmid DNA manufacturing market by 2035, owing to the robust research and development activities, coupled with increasing adoption of viral vector manufacturing for a wide range of therapies. Notably, major industry CMOs such as Cytiva, Pfizer, Resilience and uniQure have viral vector manufacturing facilities in the US.
The market in Asia-Pacific is likely to grow at a relatively high CAGR (11%), during the forecast period till 2035. This is a result of increased healthcare spending and government initiatives to improve healthcare infrastructure, along with a surge in number of clinical trials for viral vector-based therapies in this region.
The increasing number of gene therapy clinical trials and market approvals are the key drivers for demand for viral and non-viral vectors, as development of each therapy requires a consistent supply of high-quality vectors. Further, technological advancements in vector engineering and manufacturing processes, such as the use of improved cell lines and purification techniques, have significantly enhanced production capacity, vector quality, and safety profiles. These advancements also contribute to cost reduction, facilitate regulatory compliance, and support the expanding pipeline of gene therapy products.
Additionally, the rising prevalence of genetic diseases and the growing investment in research and development within the gene therapy sector contribute significantly to the market's growth, creating a strong demand for viral vector manufacturing services.
The vector-based manufacturing market faces several challenges primarily due to high complex manufacturing process demanding specialized expertise, advanced equipment and stringent quality controls.
Stakeholders in this domain have entered into numerous partnerships and collaborations, allowing them to expand their respective offerings and enhance their capabilities and visibility in this domain. In terms of partnerships, product manufacturing agreement, acquisition, licensing agreement and product development and manufacturing agreement have emerged as the most popular engagement models.
In July 2025, ProBio entered into a collaboration with ACT therapeutics for the development and production of plasmid and virus vectors for the first pipeline of latter's advanced CAR-T platform.
In May 2025, Forge Biologics collaborated with Fractyl Health to develop and produce AAV vectors, supporting the advancement of Fractyl Health’s gene therapy platform for the treatment of metabolic diseases.
Players in this domain are expanding their capability in order to enhance their portfolio. For viral vector and plasmid DNA manufacturing, facility expansion has emerged as the most popular engagement model.
In July 2025, ProBio, a subsidiary of GenScript Biotech, opened its flagship Cell and Gene Therapy Center of Excellence at the Princeton West Innovation Campus in Hopewell, New Jersey; a 128,000 sqft, GMP-compliant facility. The purpose is to manufacture high-quality plasmid DNA and viral vectors, including adeno-associated virus and lentiviral vector platforms.
In February 2025, Novartis opened a USD 41.2 million fully automated viral vector facility in Slovenia, marking its first step into viral vector production in Europe. The new site, called VIFA One will support the development of cell and gene therapies for cancer and other serious diseases. Equipped with advanced robotics, the plant can manage all stages of production at a single location. With this launch, Novartis’ total investment in Slovenia has reached USD 3.6 billion, underscoring the company’s long-term commitment to the country’s biopharmaceutical ecosystem.
Technological advancements are rapidly transforming the viral vector manufacturing landscape. Innovations in cell culture technologies, such as the development of improved cell lines and optimized culture conditions, have significantly increased vector yields and reduced production costs. Advancements in downstream processing, including chromatography and filtration techniques, have enhanced the purity and safety of viral vectors.
The market report presents an in-depth analysis, highlighting the capabilities of various stakeholders in the viral vector & plasmid manufacturing industry, across different geographies. Amongst other elements, the market report includes:
| Key Report Attributes | Details | |
| Historical Trend | Since 2021 | |
| Forecast Period | Till 2035 | |
| Market Size 2025 | $ 843 Million | |
| Market Size 2035 | $ 2,161 Million | |
| CAGR (Till 2035) | 9.87% | |
| Scale of Operation |
|
|
| Application Area |
|
|
| Type of Vector Manufactured |
|
|
| Therapeutic Area |
|
|
| Type of Manufacturer |
|
|
| Geographical Regions |
|
|
| Excel Data Packs (Complimentary) |
|
|
| Key Players Profiled |
|
|
| PowerPoint Presentation (Complimentary) |
Available | |
| Customization Scope | 15% Free Customization | |
